OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb entered a global collaboration and license agreement with Eli Lilly for a new ion channel program, leveraging its Biological Intelligence platform. The terms include an upfront payment and eligibility for up to $370 million in milestone payments, alongside tiered royalties on global net sales.
Key figures
- Deal Value Usd
- $370 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.